Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 182

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Siglec‐8 on human eosinophils and mast cells, and Siglec‐F on murine eosinophils, are functionally related inhibitory receptors

Open access
Bochner, B. S. · 2009 · Clinical & Experimental Allergy

Abstract

Summary: Siglecs (sialic acid‐binding, Ig‐like lectins) are a family of single‐pass transmembrane cell surface proteins found predominantly on leucocytes. Their unique structural characteristics include an N‐terminal carbohydrate‐binding (‘lectin’) domain that binds sialic acid, followed by a variable number of Ig‐like domains, hence these structures are a subset of the Ig gene superfamily. Another unique feature of Siglecs is that most, but not all, possess so‐called immunoreceptor tyrosine‐based inhibitory motifs in their cytoplasmic domains, suggesting that these molecules function in an inhibitory capacity. Siglec‐8, the eighth member identified at the time, was discovered as part of an effort initiated almost a decade ago to identify novel human eosinophil and mast cell proteins. Since that time, its selective expression on human eosinophils and mast cells has been confirmed. On eosinophils, Siglec‐8 engagement results in apoptosis, whereas on mast cells, inhibition of FcɛRI‐dependent mediator release, without apoptosis, is seen. It has subsequently been determined that the closest functional paralog in the mouse is Siglec‐F, selectively expressed by eosinophils but not expressed on mast cells. Despite only modest homology, both Siglec‐8 and Siglec‐F preferentially recognize a sulphated glycan ligand closely related to sialyl Lewis X, a common ligand for the selectin family of adhesion molecules. Murine experiments in normal, Siglec‐F‐deficient mice and hypereosinophilic mice have resulted in similar conclusions that Siglec‐F, like Siglec‐8, plays a distinctive and important role in regulating eosinophil accumulation and survival in vivo. Given the resurgent interest in eosinophil‐directed therapies for a variety of disorders, plus its unique additional ability to also target the mast cell, therapies focusing on Siglec‐8 could some day prove to be a useful adjunct to our current armamentarium for the treatment of asthma, allergies and related disorders where overproduction and overactivity of eosinophils and mast cells is occurring.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2222.2008.03173.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 182

Metadata

Authors
Bochner, B. S.
Venue
Clinical & Experimental Allergy
Publisher
Wiley
Published
2009-01-28
Volume
39
Issue
3
Pages
317-324
ISSN
  • 0954-7894 (ISSN-L)
  • 1365-2222
OpenAlex
W2002474633
Cited by
182
References
2
FWCI
4.20
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Siglec‐8 on human eosinophils and mast cells, and Siglec‐F on murine eosinophils, are functionally related inhibitory receptors. https://app.cochat.ai/papers/10.1111/j.1365-2222.2008.03173.x
The paper
Bochner, B. S. (2009). Siglec‐8 on human eosinophils and mast cells, and Siglec‐F on murine eosinophils, are functionally related inhibitory receptors. Clinical & Experimental Allergy. https://doi.org/10.1111/j.1365-2222.2008.03173.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.